0      0

Precision Oncology: Translating Discovery to the Clinic | EK45


ORIC-944, a Potent and Selective Allosteric PRC2 Inhibitor, Mediates Antitumor Efficacy Through Distinct Mechanisms in Two Prostate Cancer Xenograft Models


Jun 21, 2021 12:00am ‐ Jun 21, 2021 12:00am

Speaker(s):

You must be logged in and own this session in order to post comments.